Literature DB >> 8901068

Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.

C J Porter1, S A Charman, A J Humberstone, W N Charman.   

Abstract

The intestinal lymphatic transport of halofantrine, an important, highly lipophilic antimalarial drug, has been studied in a conscious rat model after oral administration. In these studies, the lymphatic transport of Hf free base when coadministered with lipid was approximately 20% of the administered dose compared with 5% transport after administration of the HCl salt with or without lipid. These differences in transport can be attributed to the increased lipophilicity of the free base (relative to the HCl salt) thereby facilitating greater association of Hf base with the products of luminal lipid digestion and the subsequent interaction with the intestinally derived chylomicrons responsible for lymphatic drug transport. In contrast to previous results in an anesthetized rat model where lymphatic transport was dependent on the characteristics of the intraduodenally administered lipid formulations, the lymphatic transport of Hf base in the conscious rat was independent of both the class of administered lipid (triglyceride or fatty acid) and the extent of formulation dispersion (micellar lipid or lipid solution). Considering the different lymphatic transport profiles of Hf base in the anesthetized and conscious rat models, it is proposed that the lipid vehicle effects observed in the intraduodenally dosed anesthetized model most likely reflects the lack of gastric processing by preduodenal lipase and the shear action of the stomach otherwise present in the conscious rat model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901068     DOI: 10.1021/js9502229

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport.

Authors:  Natalie L Trevaskis; Suzanne M Caliph; Gary Nguyen; Patrick Tso; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2013-02-21       Impact factor: 4.200

2.  The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

Authors:  Natalie L Trevaskis; Luojuan Hu; Suzanne M Caliph; Sifei Han; Christopher J H Porter
Journal:  J Vis Exp       Date:  2015-03-06       Impact factor: 1.355

3.  Structured triglyceride vehicles for oral delivery of halofantrine: examination of intestinal lymphatic transport and bioavailability in conscious rats.

Authors:  René Holm; Christopher J H Porter; Anette Müllertz; Henning G Kristensen; William N Charman
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats.

Authors:  Mette Grove; Jeanet L Nielsen; Gitte P Pedersen; Anette Müllertz
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.200

5.  Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids.

Authors:  R Holm; A Müllertz; G P Pedersen; H G Kristensen
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions.

Authors:  S Watnasirichaikul; N M Davies; T Rades; I G Tucker
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

7.  The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles.

Authors:  Natalie L Trevaskis; Ravi M Shanker; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2010-07-16       Impact factor: 4.200

8.  Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats.

Authors:  Ditte M Karpf; René Holm; Henning G Kristensen; Anette Müllertz
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

9.  Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs.

Authors:  Shui-Mei Khoo; David M Shackleford; Christopher J H Porter; Glenn A Edwards; William N Charman
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 10.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.